Nome Químico: (1S,2S,3R,5S)-3-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Sinônimo: Ticagrelor USP Related Compound B
Sorrisos: OCCO[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC2=NC(SCCC)=NC3=C2N=NN3[C@H]4[C@H](C5=CC(F)=C(F)C=C5)C4)C1
Inchi: InChI=1S/C12H21NO5.C4H6O6/c1-4-15-9(14)6-16-8-5-7(13)10-11(8)18-12(2,3)17-10;5-1(3(7)8)2(6)4(9)10/h7-8,10-11H,4-6,13H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t7-,8+,10+,11-;1-,2-/m11/s1
Estimation Of Ticagrelor In Commercial Dosage Form Using A Sensitive Validated RP-HPLC Method
By Madhuri, K.; Rao, Y. Srinivasa; Varaprasada, Rao K.; Deepthi, R.
From World Journal of Pharmaceutical Research (2021), 10(6), 1281-1292.
Development and validation of stability indicating RP-HPLC method for the estimation of Ticagrelor by forced degradation studies
By Dole, Manjusha; Kendre, Meenakshi; Wagh, Viplav
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(5), 711-724
Development of a validated HPLC-PDA method for stability indicating study of ticagrelor: a novel anti-platelet agent (P2Y12-ADP receptor blocker)
By Sulthana, Shabana; Anuradha, V.; Rao, Mandava V. Basaveswara
From International Journal of Pharmaceutical, Chemical and Biological Sciences (2017), 7(1), 36-42